Discovery Platform
Nigeria Indigenous Botanical Active Screening (OEM Services)
Targeted bioactivity profiling, LC-MS fractionation, and high-yield compound isolation for West African flora candidates.
View Service Specs →
Targeted bioactivity profiling, LC-MS fractionation, and high-yield compound isolation for West African flora candidates.
View Service Specs →
Cellular mechanistic studies including anti-inflammatory, antioxidant, antipathogenic, and metabolic pathway assays.
View Service Specs →
Acute toxicity (LD50), sub-chronic dosing, and targeted therapeutic disease models verifying in vivo efficacy profiles.
View Service Specs →
Standardized chromatographic fingerprinting, reference marker calibration, and commercial batch validation protocols.
View Service Specs →A strategic analysis of market drivers, regulatory mandates from the National Agency for Food and Drug Administration and Control (NAFDAC), and global contract research opportunities for West Africa.
Nigeria represents sub-Saharan Africa’s largest consumer healthcare market, with a population exceeding 220 million and an expanding demand for both chronic disease therapeutics and accessible wellness formulations. Historically, over 70% of finished pharmaceuticals and near 95% of active pharmaceutical ingredients (APIs) consumed in Nigeria have been imported from foreign manufacturers. In recent years, acute foreign exchange volatility, escalating logistics tariffs, and supply chain disruptions have compelled domestic manufacturers in Lagos, Kano, Onitsha, and Ibadan to pivot toward localized supply chain resilience.
Concurrently, Nigeria is recognized by international ethnobotanists as an epicenter of botanical biodiversity. Indigenous flora such as Vernonia amygdalina (Bitter Leaf), Garcinia kola (Bitter Kola), Zanthoxylum zanthoxyloides (Fagara), Moringa oleifera, and Cryptolepis sanguinolenta possess potent anti-infective, anti-inflammatory, hepatoprotective, and antisickling chemical entities. However, commercial exploitation has historically been stunted by unstandardized decoctions, batch inconsistency, and lack of reproducible pharmacological documentation.
NAFDAC's revised regulations for herbal medicines and dietary supplements demand rigorous analytical proof of active ingredients, chromatographic identification (HPTLC/HPLC fingerprints), toxicological safety assays (acute, sub-chronic toxicity), and microbial/heavy-metal purity limits. Raw botanical claims are no longer sufficient; global CRO validation is becoming an essential prerequisite for pharmaceutical dossier registration.
Our OEM Active Ingredients Screening platform directly bridges this industrial gap. By operating as an internationally accredited contract research organization (CRO) and contract development and manufacturing organization (CDMO), we furnish Nigerian pharmaceutical champions with laboratory-to-commercial solutions, converting indigenous raw materials and targeted botanical matrices into standardized, compliant, and commercially viable APIs.
| Screening Dimension | Traditional Empirical Practice | Modern OEM/CDMO Scientific Standard |
|---|---|---|
| Source Authentication | Morphological visual inspection | DNA barcoding, HPTLC chemical fingerprinting |
| Marker Quantification | Crude extraction ratios (e.g., 10:1) | Targeted HPLC/GC-MS active content assay (≥98% precision) |
| Safety Profiling | Anecdotal historical ingestion | OECD-compliant LD50, Ames test, cell-based cytotoxicity |
| Batch Reproducibility | High seasonal variation | Validated standard operating procedures & pilot CDMO controls |
| Regulatory Dossier | Minimal descriptive monographs | Complete CTD/NAFDAC-ready analytical & clinical data dossiers |
On a global scale, the botanical active ingredients market is expanding at a CAGR exceeding 8.4%, shifting away from rudimentary dry extracts toward clinically validated, single-molecule or enriched-fraction phytochemicals. Modern biopharmaceutical discovery utilizes metabolomics and phenotypic screening to evaluate multi-target botanical synergies—often termed "reverse pharmacology."
MedGence (Yineng Pharma) stands at the forefront of this convergence. By uniting 14+ years of Traditional Chinese Medicine (TCM) modernization with high-resolution analytical infrastructure, we afford our Nigerian partners access to international research pipelines that shorten time-to-market and lower capital expenditure.
Our Changsha R&D center and automated CDMO facilities provide direct scientific backing for complex phytochemical isolation projects.
Deploying high-precision screening and OEM active supply across key consumer healthcare, clinical therapy, and industrial cosmetic segments.
Malaria, microbial drug resistance, and enteric infections remain public health challenges across West Africa. We screen potent quinoids, sesquiterpene lactones, and alkaloids from plant sources, standardizing dosage parameters to support regional antimalarial adjuncts and immune-boosting preparations.
With changing urban dietary patterns in Lagos and Abuja, diabetes, hypertension, and dyslipidemia are rising steadily. Our active screening targets alpha-glucosidase inhibitors, berberine analogs, and polyphenolic complexes from botanical origins to formulate clinically verifiable metabolic solutions.
Nigeria bears the highest burden of sickle cell disease globally. Drawing on historical breakthroughs (such as phytomedicine-based antisickling formulas), our contract screening assays examine erythrocyte membrane stabilization, antisickling kinetics, and fetal hemoglobin induction from natural actives.
The Nigerian beauty and personal care industry is one of the fastest-growing on the African continent. We screen bioactive components from Shea butter unsaponifiables, Cocoa polyphenols, and Bitter Kola triterpenes for hyperpigmentation control, UV photoprotection, and skin barrier repair.
Gastric ulcers and hepatitis challenge local populations due to environmental pathogens. Screening of flavonoid-rich and polysaccharide fractions yields potent mucosal protective barriers and hepatic antioxidant regeneration profiles suitable for tonic and sachet product formats.
To combat pediatric malnourishment and adult micronutrient deficiencies in rural and urban clusters, we formulate water-dispersible vitamin-dense herbal extracts (e.g., Moringa, Hibiscus sabdariffa) tailored for RTD beverages, malt beverages, and fortified food matrices.
A structured scientific framework moving raw botanical matrices from primary screening to high-volume commercial production.
Multidimensional chemical profiling using UPLC-QTOF-MS. High-throughput in vitro binding and cellular phenotypic assays identify active fractions, discarding inert compounds early in development.
Supercritical CO2, macroporous resin adsorption, and prep-HPLC fractionation isolate targeted fractions. Establishment of validated HPTLC/HPLC standard operating methods for QC departments.
Rigorous toxicological screening: Acute LD50, 28/90-day repeat dose, Ames mutagenicity, and targeted disease animal models generating full safety datasets for regulatory review.
Tech transfer from pilot extraction vessels into cGMP manufacturing lines. Delivery of pharmaceutical-grade active powders, concentrates, or shelf-ready finished dosage forms under strict NDA protection.
Solving critical supply chain, technical, and regulatory barriers with modular contract development packages.
Ideal for companies sourcing regional raw botanicals but lacking high-yield industrial purification equipment. We optimize extraction yield, solvent recovery, and stability, transferring turnkey recipes to your plant or supplying toll extraction.
Review Process Capabilities →We provide comprehensive analytical method validation, Certificate of Analysis (CoA) generation, stability data under Zone IVb (hot/humid) climatic testing conditions, and complete preclinical study reports for registration.
Request Dossier Guidance →Supply of bulk standardized botanical powders, concentrates, or finished consumer-ready forms (hard gelatin capsules, liquid vials, blister tablets, and micro-granules) shipped directly to Lagos or Port Harcourt ports.
Download Dosage Catalog →Preserving original accredited R&D services with customized application pathways for Nigerian importers, distributors, and pharmaceutical manufacturers.
Comprehensive botanical compound profiling, screening bioactive markers for pharmacological formulations and health products.
Inquire This Service →
Targeting indigenous African raw materials, isolating bioactive glycosides, flavonoids, and therapeutic polyphenols.
Inquire This Service →
Cell-based mechanistic screening, assessing cytotoxicity, enzyme inhibition, and molecular receptor binding kinetics.
Inquire This Service →
OECD-compliant in vivo animal protocols: Acute toxicity, sub-chronic toxicity, and pharmacodynamic therapeutic modeling.
Inquire This Service →
Multi-center clinical trial designs, cohort studies, and post-market safety surveillance supporting New Drug Applications (NDAs).
Inquire This Service →
Quantifying geographical and seasonal potency variations to lock in the highest active yield and reduce batch variability.
Inquire This Service →
Developing reproducible chromatographic methods (HPLC, HPTLC, GC-MS) and quality specs for regulatory submissions.
Inquire This Service →
High-speed capsule filling, tableting, blister packaging, and oral liquids produced under cGMP with customs clearance support.
Inquire This Service →Everything R&D Directors, Procurement Managers, and Regulatory Affairs Officers need to know about partnering with MedGence (Yineng Pharma).
Partner with an established natural medicine CRO/CDMO. Whether you require active ingredient identification, NAFDAC-compliant analytical data, or commercial OEM bulk supply for the Nigerian market, our scientific team is ready to assist.